Dr Hilary McElwaine-Johnn is a Physician with over 20 years’ experience in drug development, most recently within venture capital backed biotech companies. Prior to joining PsiOxus in December 2015, Hilary was Chief Medical Officer at Vantia Therapeutics from 2008. Hilary has experience with small molecules and biologics across multiple phases of development in a broad range of therapeutic areas including immunotherapeutics and cancer vaccines. From 2004, Hilary was Vice President Clinical at PowerMed, responsible for clinical development of DNA based vaccines for influenza, chronic viral diseases and cancer, prior to its successful acquisition by Pfizer.
Hilary is a graduate of Imperial College London and St Mary’s Hospital Medical School and is a Member of Royal College of Physicians and of the Faculty of Pharmaceutica Medicine.